These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 33090432)

  • 21. Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trial.
    Sánchez Barrueco Á; Mateos-Moreno MV; Martínez-Beneyto Y; García-Vázquez E; Campos González A; Zapardiel Ferrero J; Bogoya Castaño A; Alcalá Rueda I; Villacampa Aubá JM; Cenjor Español C; Moreno-Parrado L; Ausina-Márquez V; García-Esteban S; Artacho A; López-Labrador FX; Mira A; Ferrer MD
    Emerg Microbes Infect; 2022 Dec; 11(1):1833-1842. PubMed ID: 35796097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CPC-containing oral rinses inactivate SARS-CoV-2 variants and are active in the presence of human saliva.
    Anderson ER; Patterson EI; Richards S; Pitol AK; Edwards T; Wooding D; Buist K; Green A; Mukherjee S; Hoptroff M; Hughes GL
    J Med Microbiol; 2022 Feb; 71(2):. PubMed ID: 35180046
    [No Abstract]   [Full Text] [Related]  

  • 23. The efficacy of mouthwashes in reducing SARS-CoV-2 viral loads in human saliva: A systematic review.
    Ziaeefar P; Bostanghadiri N; Yousefzadeh P; Gabbay J; Shahidi Bonjar AH; Ghazizadeh Ahsaie M; Centis R; Sabeti M; Sotgiu G; Migliori GB; Nasiri MJ
    New Microbes New Infect; 2022; 49():101064. PubMed ID: 36530834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mouth rinses efficacy on salivary SARS-CoV-2 viral load: A randomized clinical trial.
    Alzahrani MM; Bamashmous S; Alkharobi H; Alghamdi A; Alharbi RH; Hassan AM; Darwish M; Bukhari A; Mahmoud AB; Alfaleh MA; Mirza AA; Abuzenadah AM; Abujamel TS; Hashem AM
    J Med Virol; 2023 Jan; 95(1):e28412. PubMed ID: 36527332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized clinical trial to assess the impact of oral intervention with cetylpyridinium chloride to reduce salivary SARS-CoV-2 viral load.
    Tarragó-Gil R; Gil-Mosteo MJ; Aza-Pascual-Salcedo M; Alvarez MJL; Ainaga RR; Gimeno NL; Viñuales RF; Fernández YM; Marco JM; Bolsa EA; Sancho JB; Cajo SA; Perez-Zsolt D; Raïch-Regué D; Muñoz-Basagoiti J; Izquierdo-Useros N; Pociello VB; León R; Peris DS
    J Clin Periodontol; 2023 Mar; 50(3):288-294. PubMed ID: 36345827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preprocedural Mouthwashes for Reduction of SARS-CoV-2 Viral Load and Infectivity.
    Cieplik F; Jakubovics NS
    J Dent Res; 2022 Nov; 101(12):1421-1423. PubMed ID: 35897159
    [No Abstract]   [Full Text] [Related]  

  • 27. Could mouth rinses be an adjuvant in the treatment of SARS-CoV-2 patients? An appraisal with a systematic review.
    Gandhi G; Thimmappa L; Upadhya N; Carnelio S
    Int J Dent Hyg; 2022 Feb; 20(1):136-144. PubMed ID: 34628705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An exploratory study of drug concentration and inhibitory effect of cetylpyridinium chloride buccal tablets on SARS-CoV-2 infection among 10 Chinese subjects.
    Li Y; Xie Z; Chen L; Liu X; Li S; Ye S; Tang H; Lee C; Gu Q; Men F; Zhang J; Hu D; Jiang Y; Wang X; Wang Q; Feng Y; Niu S; Liu Y; Fang Y
    Fundam Clin Pharmacol; 2024 Jun; 38(3):579-587. PubMed ID: 37985697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of Pre-Procedural Mouthwashes against SARS-CoV-2: A Systematic Review of Randomized Controlled Trials.
    Garcia-Sanchez A; Peña-Cardelles JF; Ruiz S; Robles F; Ordonez-Fernandez E; Salgado-Peralvo AO; Balloch J; Simon JC
    J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35330016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of mouthrinses in reducing oral SARS-COV-2 load: a review.
    Pannuti CM; Reis INRD; Souza NV; Souto MLS; Silva CGB; Bezinelli LM; Machado CM; Romito GA; Villar CC
    Braz Oral Res; 2023; 37():e038. PubMed ID: 37132726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chlorhexidine mouthwash reduces the salivary viral load of SARS-CoV-2: A randomized clinical trial.
    Costa DD; Brites C; Vaz SN; de Santana DS; Dos Santos JN; Cury PR
    Oral Dis; 2022 Nov; 28 Suppl 2():2500-2508. PubMed ID: 34837305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virucidal Activity of Different Mouthwashes against the Salivary Load of SARS-CoV-2: A Narrative Review.
    Garcia-Sanchez A; Peña-Cardelles JF; Salgado-Peralvo AO; Robles F; Ordonez-Fernandez E; Ruiz S; Végh D
    Healthcare (Basel); 2022 Mar; 10(3):. PubMed ID: 35326947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiviral Activity of Reagents in Mouth Rinses against SARS-CoV-2.
    Carrouel F; Gonçalves LS; Conte MP; Campus G; Fisher J; Fraticelli L; Gadea-Deschamps E; Ottolenghi L; Bourgeois D
    J Dent Res; 2021 Feb; 100(2):124-132. PubMed ID: 33089717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of SARS-CoV-2 salivary viral load with pre-procedural mouth rinses: a randomised, controlled, clinical trial.
    Farmaha JK; James JN; Frazier K; Sahajpal NS; Mondal AK; Bloomquist DT; Kolhe R; Looney SW; Bloomquist R
    Br Dent J; 2023 Apr; 234(8):593-600. PubMed ID: 37117367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virucidal efficacy of chlorhexidine: a systematic review.
    Fernandez MDS; Guedes MIF; Langa GPJ; Rösing CK; Cavagni J; Muniz FWMG
    Odontology; 2022 Apr; 110(2):376-392. PubMed ID: 34637092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of the use of nasal and oral antiseptics during a global pandemic.
    Stathis C; Victoria N; Loomis K; Nguyen SA; Eggers M; Septimus E; Safdar N
    Future Microbiol; 2021 Jan; 16(2):119-130. PubMed ID: 33464122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of mouthwashes in the management of COVID-19 patients in intensive care units: recommendations and current evidence.
    Tovani-Palone MR; Shamsoddin E
    Einstein (Sao Paulo); 2021; 19():eCE6419. PubMed ID: 33787663
    [No Abstract]   [Full Text] [Related]  

  • 38. Potential Role of Oral Rinses Targeting the Viral Lipid Envelope in SARS-CoV-2 Infection.
    O'Donnell VB; Thomas D; Stanton R; Maillard JY; Murphy RC; Jones SA; Humphreys I; Wakelam MJO; Fegan C; Wise MP; Bosch A; Sattar SA
    Function (Oxf); 2020; 1(1):zqaa002. PubMed ID: 33215159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Povidone-Iodine Solution: A Potential Antiseptic to Minimize the Risk of COVID-19? A Narrative Review.
    Castro-Ruiz C; Vergara-Buenaventura A
    J Int Soc Prev Community Dent; 2020; 10(6):681-685. PubMed ID: 33437699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mouthwashes with CPC Reduce the Infectivity of SARS-CoV-2 Variants In Vitro.
    Muñoz-Basagoiti J; Perez-Zsolt D; León R; Blanc V; Raïch-Regué D; Cano-Sarabia M; Trinité B; Pradenas E; Blanco J; Gispert J; Clotet B; Izquierdo-Useros N
    J Dent Res; 2021 Oct; 100(11):1265-1272. PubMed ID: 34282982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.